The Canadian Early Arthritis Cohort Study, was a real-world patient study looking at adherence to early DMARD strategies in newly diagnosed rheumatoid arthritis (RA) patients seen in routine care. In this touchIMMUNOLOGY interview, it was a pleasure to talk with Dr. Janet Pope (University of Western Ontario, London, ON, Canada) to discuss the importance of patient adherence to therapy in RA, the aims, design and findings of the study and what needs to be done in terms of further study to optimise adherence.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Adherence to Early DMARD Strategies in Newly Diagnosed RA Patients Seen in Routine Care: Results from the Canadian Early Arthritis Cohort Study‘ (Abstract number: 1358) was presented at the ACR Convergence, November 10–14, 2022.
Questions
- What is known about the importance of patient adherence to therapy in rheumatoid arthritis? (0:16)
- What were the aims and design of your study? (0:35)
- What were the study findings and what reasons were given for non-adherence? (1:37)
- What further study is needed to optimise adherence? (3:28)
Disclosures: Janet Pope has nothing to disclose in relation to this video interview.
Support:Â Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ACR Convergence 2022.
